Xencor stock skyrockets 26% overnight after breakthrough in cancer research

Xencor, Inc., a clinical-stage biopharmaceutical company specializing in engineered antibodies for cancer treatment, saw its stock rise by 26% to $20.39 on Monday following substantial ... Read More